Skip to content

Effectiveness of Adjuvant Supplements Prior to in IVF

To Investigate the Effectiveness of Adjuvant Supplements Prior to in Vitro Fertilization Cycles

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05471453
Enrollment
70
Registered
2022-07-22
Start date
2022-03-02
Completion date
2023-12-31
Last updated
2024-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dietary Supplements

Keywords

DHEA, CoQ10, Tocotrienol, poor ovarian responder, in vitro fertilization

Brief summary

To investigate the effect of combined DHEA, CoQ10 and tocotrienol on IVF cycles in poor ovarian responders

Detailed description

Background There is a trend for delayed marriage and childbearing worldwide. Women undergoing in vitro fertilization (IVF) cycles are getting older. Women with advanced age are more likely to be poor ovarian responders (PORs) who have poor prognosis in IVF cycles. Numerous studies have shown that DHEA supplementation may improve IVF outcomes in PORs. Additionally, due to poor prognosis of PORs, it is quite common to combine multiple therapies instead of just one treatment. Some studies showed that CoQ10 and tocotrienol are beneficial for fertility. Thus, the aim of this study is to investigate the effect of combined DHEA, CoQ10 and tocotrienol on IVF cycles in PORs. Objective To investigate the effect of combined DHEA, CoQ10 and Tocotrienol on PORs undergoing IVF cycles Methods The study will be conducted from March 1st, 2022 to December 31st, 2023 in our reproductive center. We plan to enroll 120 PORs undergoing IVF cycles and divided them into four groups: (1) DHEA (n=30): 75 mg DHEA supplementation per day for three months; (2) DHEA + CoQ10 + Tocotrienol (n=30): 75 mg DHEA supplementation + 30 mg CoQ10 + 300 mg Tocotrienol per day for three months; (3) Control: no supplementation. Basic characteristics, infertility history, hormone profiles and ovarian reserve will be recorded. We will recheck serum levels of DHEA-S, FSH and AMH after DHEA supplementation. Then, during the IVF cycles, cumulus cells will be collected after oocyte retrieval to analyze genes expression and mitochondrial function. We will follow reproductive outcomes after embryo transfer. Outcome The effect of combined DHEA, CoQ10 and Tocotrienol on cumulus cells and IVF outcomes in PORs

Interventions

DIETARY_SUPPLEMENTDHEA

75 mg DHEA supplementation per day for 3 months before IVF

DIETARY_SUPPLEMENTDHEA+CoQ10+Tocotrienol

75 mg DHEA supplementation + 30 mg CoQ10 + 300 mg Tocotrienol per day for 3 months before IVF

Sponsors

Kaohsiung Veterans General Hospital.
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
35 Years to 44 Years
Healthy volunteers
No

Inclusion criteria

* Age 35\ 44 * BMI18\ 30 kg/m2 * Diminished ovarian reserve (AFC\<5, AMH\<1.2 ng/ml)

Exclusion criteria

* Primary ovarian insufficiency * Congenital uterine anomaly * Severe intrauterine adhesion * Severe male factor * Chromosome anomaly * Malignancy * Donor cycle * having supplementation within 3 months

Design outcomes

Primary

MeasureTime frameDescription
Ongoing pregnancy ratethrough study completion, an average of 1.75 yearcontinuous presence of a fetal heartbeat over 12 weeks of a pregnancy

Secondary

MeasureTime frameDescription
Clinical pregnancy ratethrough study completion, an average of 1.75 yearthe presence of a fetal heartbeat at 6-7 weeks of a pregnancy
mitochondrial function of cumulus cellsthrough study completion, an average of 1.75 yearOxygen consumption rate of cumulus cells

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026